Prot #MK-3475-061-02: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and F

Project: Research project

Project Details

StatusFinished
Effective start/end date10/29/15 → 10/29/21

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-3475-061-02)